Revolution Medicines, Inc.는 임상 단계의 정밀 종양학 기업으로, RAS 의존성 암을 위한 신규 표적 치료제를 개발합니다. 이 회사의 연구 개발 파이프라인은 RAS 변이체에 결합하여 단독 요법으로 사용되거나, 다른 RAS(ON) 억제제, RAS 동반 억제제 또는 기타 치료제와 병용하여 사용되는 RAS(ON) 억제제와, RAS 의존성 암을 유지하는 협력 표적 및 경로를 억제하는 RAS 동반 억제제로 구성되어 있습니다. 이 회사의 RAS(ON) 억제제로는 daraxonrasib (RMC-6236), 고형암 치료를 위한 초기 임상 개발 단계
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
